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Exercise and inflammation 
Introduction 
Rheumatic and musculoskeletal diseases (RMDs) represent a diverse group of non-
communicable diseases that affect primarily the joints, muscles or other tissues of the 
musculoskeletal system but may also have systemic complications. The European League 
Against Rheumatism (EULAR) recognizes that there are more than 200 different RMDs, 
which affect individuals of all ages [1]. Based on a 2011 EULAR Position Paper, the most 
prevalent RMDs are: osteoarthritis (OA), rheumatoid arthritis (RA), osteoporosis, low back 
pain, ankylosing spondylitis, psoriatic arthritis, gout, fibromyalgia and connective tissue 
diseases, such as Systemic Lupus Erythematosus (SLE) and Scleroderma [1]. Collectively, 
RMDs are characterised by common symptoms – albeit this can vary according to the RMD – 
with the predominant ones being pain, joint damage, functional disability and fatigue. 
Another major characteristic of many RMDs is inflammation. Inflammation is a normal 
biological response to infection or tissue damage, which, under normal circumstances, ceases 
after the clearance of the stimulus. However, inflammatory processes are dysregulated in 
RMDs and persist in the long-term with significant detrimental consequences in personal and 
clinical outcomes, and thus, healthcare costs.  
 
A. Inflammatory response and RMDs  
Inflammation is triggered by the innate immune system, once its cells detect infection or 
tissue injury. This is done by surveillance of pathogens via the involvement of pattern 
recognition receptors, such as Toll-like receptors, on the cell surface and in the cytoplasm. In 
autoimmune rheumatic disease, such mechanisms become dysregulated and end up fostering 
a prolonged activation of chronic inflammatory responses. Nevertheless, developing 
autoimmune disease is normally prevented in humans via peripheral safety mechanisms that 
are in place to reduce host tolerance of potentially pathogenic cells [2].   
Inflammation can be distinguished in acute and chronic, each characterised by distinct 
pathways. Acute inflammation involves the local vasculature, the immune system and cells of 
an injured site. Chronic inflammation, on the other hand, which is what we see in RMDs, is 
characterized by tissue damage from inflammatory processes, as well as a progressive change 
in the type of immune cells that are presented in the affected inflamed tissues. There is also a 
distinction between RMDs with regards to the way that inflammation ensues. For example, 
RA and SLE are autoimmune RMDs which means that autoantibodies (i.e. antibodies 
targeting the patient’s own proteins) are produced (e.g. rheumatoid factor and anti-
citrullinated peptide antibodies in RA and anti-nuclear or anti-DNA antibodies in SLE). On 
the other hand, OA which was traditionally considered a non-inflammatory arthropathy 
because neutrophils were not present in the synovial fluid, is also now considered to have an 
early and long-term inflammatory component [3], as denoted by the production of cytokines 
which are overexpressed in the synovium of OA patients (although at much lower 
concentrations compared to RA) [4]. It is not within the scope of this review to describe in 
detail the pathogenic processes involved in each individual RMD, but dysregulation of 
cytokine production and perpetuation of inflammation is a common characteristic in all 
RMDs.  
Cytokines mediate inflammatory responses in RMDs in many different ways. Pro-
inflammatory cytokines, such as Tumour Necrosis Factor alpha (TNFα), Interleukins 1 (IL-1) 
and 6 (IL-6) mediate inflammatory pathways in RMDs, often acting in a synergistic manner. 
Their kinetics/expression seem to be involved in a vicious cycle where one may trigger an 
overexpression of the others. The pleiotropic effects of cytokines are not only involved in the 
pathogenesis of articular damage in RMDs but they also may explain several of their 
systemic manifestations and comorbidities.  
Pharmacological interventions are the mainstay treatment of inflammation in RMDs 
but despite significant advances in drug availability and therapeutic strategies in recent 
decades, there remains a significant treatment deficit. Other interventions with anti-
inflammatory potential are, therefore, of importance: a major one is increased physical 
activity. Physical activity is any bodily movement that increases energy expenditure above 
resting levels, such as walking and doing household activities. Exercise is part of physical 
activity and is a planned and structured behaviour, such as swimming or exercising in the 
gym three days a week at specific intensities, that aims to improve specific outcomes, such as 
functional ability or cardiorespiratory fitness. In the last two decades, a significant amount of 
work has been conducted to better understand the effects of exercise on inflammatory 
processes both in the healthy and populations with non-communicable disease. The potential 
benefits of exercise are recognized and included in recent EULAR projects and 
recommendations focusing on implementation of physical activity and exercise as 
“adjuvants” to improve disease-related symptoms and comorbidities in RMDs [5-8]. The 
present review focuses on the contribution of inflammatory mediators (with a special focus 
on cytokines as the overarching factor) on disease-related outcomes and systemic 
manifestations in RMDs, and discusses how exercise dosage, in particular exercise intensity, 
can mitigate the effects of inflammatory mediators on different outcomes. 
 
B. Exercise and inflammation 
Assessing inflammation as a process is difficult due to the multiple cells, mediators and 
pathways involved. Exercise-induced effects on inflammation have additional complexity, 
since they depend on resident macrophages, which exert different effects on different 
processes depending on the tissue they reside. In this review, the effects of exercise on 
inflammation will, therefore, be discussed in the context of local, tissue-specific responses.  
The target of any intervention in RMDs is remission.  Remission conventionally 
includes significant reductions below certain thresholds of some clinical outcomes (e.g. pain) 
and markers of the acute phase response (usually the erythrocyte sedimentation rate-ESR, a 
major determinant of which is fibrinogen, or the acute phase reactant, C-reactive protein-
CRP). The acute phase response is regulated by specific pro-inflammatory cytokines, 
predominantly IL-6. When it comes to assessing the effects of exercise on inflammation, the 
main focus has been on the local and systemic effects of pro-inflammatory cytokines with the 
majority of studies having been conducted in athletes and/or the general population. No 
experimental studies exist to date that have investigated the effects of exercise on 
inflammation in RMDs as a primary outcome, as denoted in two relevant recent meta-
analyses in RMDs investigating the effects of physical activity and/or exercise on disease 
activity and inflammatory markers [9, 10].  
 
B.1. Exercise and Cytokines 
Early sports science studies revealed a marked increase in circulating IL-6 in response to 
prolonged endurance exercise [11]. Prior to 2000, it was hypothesized that this was the result 
of muscle damage and subsequent inflammation. Indeed, following marathon running, 
significant increases were detected in IL-6 mRNA in muscle biopsies and subsequent 
circulating IL-6, which prompted researchers to suggest that prolonged exercise results in 
damage in muscle fibres, releasing IL-6 in the circulation and triggering an inflammatory 
response [12]. This hypothesis was supported by other studies, which revealed associations 
between creatine kinase (a frequent biomarker used to evaluate muscle damage) and serum 
IL-6 following high-intensity exercise [13]. This was later questioned, since well-controlled 
non-damaging exercise protocols still revealed a significant elevation in IL-6 [14]. However, 
the balance of evidence is that muscle damaging (e.g. eccentric) exercise, particularly in 
untrained people, such as patients with RMDs, does cause an inflammatory response. The 
effects of prolonged high-intensity exercise-induced muscle damage on inflammation are 
well described, with neutrophils and macrophages infiltrating the damaged muscle tissue up 
to 48 hours post exercise [15], suggesting that part of the elevation observed in muscular and 
circulating IL-6 may be due to activated muscle-residing macrophages in the site of injury. At 
first sight, such evidence may act as a barrier for people with RMDs to engage in exercise, 
particularly high-intensity exercise. However, this is a normal process that takes place within 
the human body to induce increases in muscle mass (and strength), which in turn can reduce 
functional disability and improve fatigue. It is also important to mention that the 
manifestations of muscle damage, or delayed onset muscle damage (DOMS), manifests with 
only mild pain which can be minimized if the high-intensity exercise protocol applies 
progressively the exercise intensity (i.e. starting from lower intensities and building up to 
high-intensity dosage).  The effects of such exercise protocols on physiological adaptations, 
local and systemic inflammation, symptoms and function in people with RMDs have not 
been evaluated.   
A growing amount of literature now supports that engagement in exercise induces an 
anti-inflammatory phenotype in the general population, both acutely as well as in the long 
term (Figure 1), even though this may be preceded by an acute inflammatory load. The 
effects of acute exercise on inflammation have been mainly investigated in the muscle by 
assessing muscle-derived cytokines termed “myokines”, while the long-term effects of 
exercise on inflammation are mainly observed in adipose tissue with adipose tissue-derived 
cytokines termed “adipokines”.  
 
B.1.1. Acute exercise and inflammation 
Muscle contraction during exercise is now thought to be the main trigger for overexpression 
of IL-6. Exercise-induced IL-6 mRNA within the muscle, increases IL-6 in the circulation 
which then acts as a trigger to activate hepatic glucogenolysis and lipolysis; this occurs 
because energy within the muscle is quickly depleted with exercise, so this mechanism 
triggers pathways to provide additional energy to the exercising muscles [16]. However, this 
overproduction of IL-6 is not thought to induce inflammation. In support of this, IL-6 in 
RMDs is induced by macrophages and necessitates the presence of TNFα, which is activated 
by the nuclear factor-kB (NF-kB) pathway [15]. In contrast, muscular exercise-induced 
production of IL-6 occurs without the presence of TNFα or NF-kB activation, and is 
regulated by an interaction between the nuclear factor of activated T-cells (NFAT) and 
glycogen-p38 mitogen activated protein kinase pathways (MAPK) [17]. These phenomena 
appear to coincide with other anti-inflammatory events. Specifically, during exercise, soluble 
TNF receptors, thought to be naturally produced inhibitors of TNFα [18], increase and 
remain elevated during and post exercise [15]. The same is true for the IL-1 receptor 
antagonist (that blocks the actions of IL-1), which is also produced during exercise and 
remains elevated post exercise [15]. At the same time, IL-1b and TNFα, which elevate and 
mediate the prolonged inflammatory responses seen in autoimmunity, remain supressed 
during a bout of exercise [15]. Furthermore, muscle-resident pro-inflammatory subtype 1 
macrophages (M1) decrease and anti-inflammatory subtype 2 (M2) macrophages increase in 
response to exercise in healthy people [19] with these effects also impacting on the 
expression of pro-inflammatory cytokines. These observations suggest that exercise may 





B.1.2. Long-term exercise and inflammation 
The long-term effects of exercise on reducing inflammation are thought to be mainly 
mediated by reductions in the size of adipose tissue. It is well-established that obesity is a 
low-grade inflammatory state with adipose tissue acting as an endocrine and paracrine organ 
responsible for stimulating the increase of inflammatory mediators. In support of this, the 
expression of inflammatory mediators such IL-6 and TNFα deriving from macrophages 
residing in adipose tissue cells, are overexpressed in overweight and obese compared to 
normal weight individuals, while inflammatory processes are activated early in the expansion 
and progression of adipose tissue [20]. On the other hand, evidence suggests that exercise can 
have a significant effect in reducing the size of adipose tissue cells. The most recent 
systematic review and meta-analysis on the effects of exercise vs. diet on adiposity included 
4,815 individuals from 117 studies and suggested that exercise results in greater loss of 
adipose tissue compared to hypocaloric diets while weight remained unchanged [21].  
 
B.2. Regulation of inflammation via induction of the peroxisome proliferator-activated 
receptor γ co-activator 1α (PGC-1α) 
 PGC1α is a transcriptional coactivator that regulates genes involved in energy metabolism 
and is the predominant regulator of mitochondrial biogenesis. PGC1α elevates rapidly during 
exercise – via the AMP-activated protein kinase (AMPK) – possibly to regulate metabolic 
fluxes in the exercising skeletal muscle as ATP reduces and metabolic demands increase with 
exercise [22]. Following exercise, PGC1α mRNA returns to pre-exercise baseline levels [23]. 
Moreover, changes in the musculature with long-term exercise, such as fiber-type switching 
towards the more oxidative type IIa and type I muscle fibers, associate with an elevation of 
PGC-1α [24]. The induction of PGC1α with exercise may potentially exert anti-inflammatory 
effects, since loss of muscle PGC-1α results in a transcriptional induction of genes that are 
mediating inflammation [25]. Specifically, in in vivo studies that used PGC-1α knockout 
animals, an increased expression of TNFα and IL-6 has been observed [26]. In theory, 
persistence of such events may suggest that more immune cells may be recruited in such 
environments, thereby, amplifying a pro-inflammatory phenotype. In addition to this, the 
anti-inflammatory effects of PGC1α may be reflected in the downregulation of oxidative 
stress mediating gene expression in vascular endothelial cells [27]. Finally, PGC1α-
dependent effects are seen within exercising muscles with regards to the polarization from 
M1 pro-inflammatory to M2 anti-inflammatory macrophages [28]. It is thought that in vivo 
muscle-induced PGC1α may not be sufficient to prevent systemic inflammation, however, it 
can promote an anti-inflammatory environment via inducing anti-inflammatory and 
suppressing pro-inflammatory cytokines [29].   
 
The biological plausibility to suggest a mediating effect of exercise on muscle and adipose 
tissue inflammation is strong but studies are available only in the general population. A 
systematic review and meta-analysis (in 1250 individuals from 11 studies) in healthy middle 
aged and older adults (similar to the age ranges observed in rheumatic diseases) suggested 
that aerobic exercise can reduce circulating IL-6 and TNFα [30]. However, relevant studies in 
inflammatory disease are currently lacking and/or lack the methodological rigour for valid 
observations. This has been highlighted in a 2019 systematic review in RA [10] and a 2017 
meta-analysis in patients with inflammatory RMDs (8) which suggested that the effects of 
exercise on inflammation are controversial or small and require further investigation. Clearly, 
much more work is necessary to understand the regulation of inflammatory and anti-
inflammatory pathways in response to short and long-term exercise engagement in people 
with RMDs.  
 
B.3. Exercise and routine serological Assessments of Inflammation 
The most common serological assessments of the effects of any intervention on inflammation 
in routine clinical practice, are the CRP and ESR.  
 
B.3.1. Exercise and CRP 
The effects of exercise on CRP has received increased scientific attention over the last decade 
in non-RMD populations. A 2016 systematic review and meta-analysis of 83 randomized 
controlled trials involving 3769 participants suggested that exercise performed for more than 
two weeks can reduce CRP [31]. This was more pronounced when exercise was accompanied 
by reductions in body mass index and fat mass, however, reductions in CRP were still evident 
even without weight loss [31]. Another 2019 meta-analysis, targeting the effects of aerobic 
exercise on CRP in healthy middle-aged and older adults (11 studies involving 1,250 
participants) confirmed these results. There is also consistency between the findings seen in 
the general population and those in some non-communicable diseases. For example, a 2016 
meta-analysis of studies involving people with cardiovascular disease (CVD) and healthy 
controls (data from 43 studies and a total of 3575 participants) revealed that exercise can 
reduce CRP to a similar extent in the two groups [32]. Similar results were observed in 
people with type 2 diabetes mellitus (meta-analysis of 14 randomised controlled trials and 
824 participants) [33]. In contrast, the aforementioned two available systematic reviews in 
RA and in inflammatory RMDs [9] did not find statistically or clinically significant effects of 
exercise on CRP. This is probably due to significant variability in the methodological designs 
of the studies included but it may also be because the size of such an effect may well be 
detectable in low-grade inflammation states (such as obesity, CVD or type 2 diabetes) but not 
in high-grade inflammation conditions, such as the RMDs. In this context, it is interesting 
that a two-year follow-up study in patients with knee OA (a low-grade inflammation RMD) 
demonstrated that higher CRP levels were related to lower gains in muscle strength [34]. 
From the mechanistic perspective, the way exercise may affect CRP levels remains 
unclear. The link between IL-6 mediated induction of the hepatic acute phase response is an 
obvious possibility. However, some epidemiological studies suggest that the effects of 
exercise on CRP levels may be due to confounders such as hypertension, body mass-related 
variables (waist-to-hip, body mass index), age and smoking with which CRP is also 
associated [35].   
 
B.3.2. Exercise and Fibrinogen 
Produced by hepatocytes in the liver and then circulating in the blood stream, fibrinogen acts 
primarily to occlude blood vessels to stop bleeding. It is also an acute phase reactant and may 
exhibit a multi-directional pro-inflammatory role, including the induction of TNFα and IL-1 
[36]. Fibrinogen acts on the affinity of red blood cells to bind with one another and is, 
therefore, a major determinant of the ESR. Fibrinogen was mainly an interest in studies 
dating 20 years ago, with longitudinal observational studies showing an average reduction of 
0.4 g/l with endurance training [37], while recent studies also suggested that lower physical 
activity associates with higher fibrinogen levels in adults with non-communicable diseases 
[38]. However, these results are contradicted in a more recent randomized controlled trial 
where no differences were detected in fibrinogen between adult women who engaged in 
intermittent brisk walking against controls [39]. Both high physical activity and 
cardiorespiratory fitness have been associated with lower fibrinogen levels in RA patients 
[40, 41]. However, in the 2019 systematic review on physical activity and inflammation in 
RA, an exercise effect on ESR was seen in only 3 of the 14 studies included [10]. Another 
meta-analysis in inflammatory RMDs (8) suggested that the effects of exercise on ESR do 
exist but they are small [9].  
 
Figure 1. Exercise may promote an anti-inflammatory phenotype in different tissues  
 
Abbreviations. PGC1α: peroxisome proliferator-activated receptor γ co-activator 1α, IL-6: 
interleukin 6, NFAT: nuclear factor of activated T-cells, MAPK: mitogen activated protein 
kinase, sTNFr: soluble tumor necrosis factor receptors, IL-1ra: interleukin 1 receptor 
antagonist, TNFα: tumor necrosis factor alpha, IL-1: interleukin 1, CRP: c-reactive protein  
 
C. Exercise can blunt inflammatory pathways which can mitigate prevalent systemic 
manifestations of RMDs 
Compared to the general population, RMDs are characterised by a higher prevalence of 
systemic manifestations / comorbidities, which have inflammation as a common 
denominator. These include loss of muscle mass, atherosclerotic CVD, insulin resistance, 
osteoporosis, depression, propensity to infections, amongst others.  The presence of such 
manifestations may, in turn, affect many significant outcomes, from falls and fractures to 
quality of life, physical function, family and social engagement, even premature death. 
Several animal and human studies (almost exclusively in people without RMDs) suggest that 
through moderating inflammatory pathways, exercise can have a beneficial impact on most of 
these systemic RMD manifestations. It is beyond the scope of this review to discuss each of 
these RMD manifestations separately: we are using two of the most prevalent and those 
where inflammation plays a critical role in their development and progression: loss of muscle 
mass and atherosclerotic CVD.  
 
C.1. Exercise, inflammation and loss of muscle mass 
In inflamamtory diseases: Loss of muscle mass has been noted in early studies of people 
suffering from rheumatic disease, with Roubenoff and colleagues observing that muscle 
wasting is probably due to cytokine-driven hypermetabolism in people with RA [42]. 
However, increased muscle mass loss has been observed in other rheumatic diseases, such as 
psoriatic arthritis [43] and SLE [44]. There has been increasing research interest to 
understand how muscle mass loss occurs in rheumatic conditions, with most of the research 
conducted in RA. The current state-of-the-art is that enhanced muscle mass loss in rheumatic 
disease seems to be due to three different factors. The first is the observed overexpression of 
cytokines that may lead to hypermetabolism and enhanced loss of muscle mass [42, 45, 46]. 
In inflammatory states, enhanced muscle proteinolysis seems to occur through the ubiquitin-
proteasome pathway where TNFα can stimulate muscle catabolism via an NF-kB process that 
increases ubiquitin conjugation to muscle proteins, resulting in protein degradation [47, 48]. 
Moreover, increased TNFα significantly affects repair processes of the muscle via the 
activation of the proteasome system and transcription factor NF-kB leading to decreased 
expression of MyoD, which is important for replenishing wasted muscle [49]. Secondly, 
physical inactivity and thus, lack of anabolic muscle stimuli can result in reduced muscle 
mass [50]. Thirdly, even a single injection of high-dose intramuscular corticosteroids in RA 
significantly reduces muscle mass with persistent effects [51]. These observations are 
substantiated in a recent systematic review and meta-analysis suggesting that at least 1/3 of 
people with RA have significant loss of muscle mass and subsequent increase in fat mass, a 
condition termed “rheumatoid cachexia” [42]. Given that one of the main mediators of 
muscle mass loss in rheumatic disease is TNFα, more recent studies focused on the effects of 
anti-TNFα medication on muscle mass of RMD patients. Interestingly, these studies 
suggested that blocking TNFα in RA patients starting anti-TNFα biologics, did not reverse 
the loss in muscle mass [52, 53]. In contrast, a controlled trial in RA revealed that unlike anti-
TNFα medication, high-intensity resistance exercise effectively increased muscle mass and 
reduce adiposity in RA patients compared to controls doing range of motion exercises only 
[54]. Unfortunately, this study did not evaluate inflammatory mediators and their effects on 
muscle mass, so this remains an area for further investigation.  
In non-inflammatory musculoskeletal disease: In some RMDs such as fibromyalgia, 
no changes in body composition have been observed compared to the general population 
[55]. However, in other RMDs this is not the case. A narrative review suggests that OA is a 
non-rheumatic disease characterized by significant loss in muscle mass [56]. Inflammation in 
the vastus lateralis in people with moderate knee OA has been implicated in the loss of 
muscle mass of OA patients compared with controls and associated with significantly higher 
IL-6 as well as inflammatory kinases such as abundance of p65 NF-κB, signal transduced and 
activator of transcription 3 c-Jun N-terminal kinase [57]. How the presence of these 
inflammatory mediators impacts on reducing muscle mass loss in OA, is still to be 
elucidated.    
 
C.2. Exercise, inflammation and atherosclerosis 
Exercise can blunt the actions of inflammatory mediators and thus, halt the induction of 
biological pathways that lead to the development and progression of atherosclerosis [58]. It is 
well-established that inflammation is involved in the development and progression of 
atherosclerosis [59]. Oxidized LDL is recognized by local tissue resident macrophages which 
take it up via their scavenger receptors in an inflammatory process characterized by the 
activation of the  NF-kB and the inflammatory cytokine genes TNFα and IL-1 [60], and form 
foam cells. The continued stimulation of TNFα from vascular macrophages in these 
atherosclerotic/inflammatory lesions recruits further monocytes to the site of vascular injury, 
resulting in a vicious cycle of inflammatory perseverance and progression of atherosclerosis. 
Even in advanced atherosclerotic plaques, macrophages are the major players in the 
continuing inflammatory responses via secreting pro-inflammatory cytokines [61].  
Exercise can blunt the processes of atherosclerosis by: a) affecting different 
macrophage functions and downstream effects on atherosclerotic plaques but also b) reducing 
oxidized LDL and thus, its associated inflammatory responses. Evidence for this derives both 
from mouse models and human studies. Firstly, activated macrophages in inflamed 
atherosclerotic plaques produce matrix metalloproteinases which in turn, lead to a disruption 
of the atherosclerotic plaque and induce thrombosis [59]. Atherosclerotic plaque 
macrophage-derived metalloproteinases 3 and 8 are downregulated in aerobically exercising 
mice while at the same time, an overexpression of the inhibitor of metalloproteinase 2 has 
been observed [62]. As previously mentioned, macrophage-derived pro-inflammatory 
cytokines from human adipose tissue are also downregulated with exercise [15]. This may be 
particularly important as increased fat deposition in adjunct coronary tissues may further 
induce an inflammatory phenotype. Indeed, obese individuals are characterized by increased 
cardiac adiposity i.e. increased epicardial fat and fatty infiltration in the myocardium. This 
phenomenon manifests with increased thickness or volume of adipose tissue layers that 
surround the heart and vessels which promotes myocardial inflammation and dysfunction 
[63]. Perivascular adipose tissue can secrete TNFα and IL-6, a mechanism that contributes to 
the ensuing presence of vascular inflammation and oxidative stress, disruption of vascular 
tone as well as intimal hyperplasia and formation, all leading to the progression of 
atherosclerosis [64]. In patients undergoing abdominal aorta surgery, it has been observed 
that perivascular aortic adipose tissue can secrete inflammatory cytokines [65], while TNFα 
and IL-6 are overexpressed in epicardial adiposity [66]. Potentially the effects of exercise to 
reduce inflammation may expand on such tissues, thereby blunting inflammatory responses 
(Figure 1). Indeed, in the absence of weight loss, exercise can reduce perivascular adipose 
tissue; it can also blunt inflammatory responses from this tissue in obese people engaging in 
strength and aerobic exercise [67]. With regards to oxidized LDL, trials on healthy and obese 
adults demonstrate that exercise can have dual effects on the oxidation of LDL and its 
subsequent regulation of inflammatory genes. These are that exercise can: a) induce 
resistance to oxidation by improving the body’s anti-oxidant capacity while at the same time 
b) reduce circulating oxidized LDL [68, 69], although the exact mechanisms are still unclear. 
Research in this field in RMDs is currently completely absent.  
 
D. Dosage of exercise and induction of anti-inflammatory responses 
The exact dosage of exercise that can improve health outcomes, including reducing 
inflammation, is an ongoing area of investigation. It is exercise rather than habitual physical 
activity that has been the main focus with regards to inflammatory responses, since exercise 
seems to have a dose-dependent relationship with health outcomes and inflammatory 
mediators. Nevertheless, new emerging areas, such as sedentary behaviours and light-
intensity activity and their impact on inflammation is a rapidly developing field in healthcare 
sciences including RMDs [70], particularly due to the observed positive associations between 
both of these with vascular dysfunction and cardiovascular risk [71].  
 Specific public health recommendations are available for physical activity 
engagement. When individuals engage in 150-300 min/week of moderate or 75-150 
min/week of strenuous physical activity coupled with resistance training twice a week, 
multiple different benefits on health can ensue. For exercise, on the other hand, the American 
College of Sports Medicine (ACSM) has conducted substantial work in defining the 
beneficial exercise dosage, using the frequency, intensity, time and type (FITT) of exercise as 







Table 1. Required dosage of exercise for health benefits from the ACSM and in RMDs 
 Aerobic Exercise Resistance Exercises 
Intensity 55-90% of HRmax 55-90% of HRmax / 60-85% of 1 RM  
Duration 20-90 min 8-12 repetitions, 2-4 sets. Exercises should induce 
fatigue but not exhaustion 
Frequency 3-5 days / week 2-3 days / week 
Abbreviations: HRmax: maximum heart rate, RM: repetition maximum 
 
It is agreed currently that, although a minimum dosage is required to increase 
cardiorespiratory fitness, the lack of consistent findings in this area is an issue of concern, 
and predominantly influenced by the initial level of fitness / conditioning of the exercising 
participants [73]. This is also the case in RMDs. Baseline levels of cardiorespiratory fitness 
as well as levels of physical activity are low in people with RMDs [7, 41] and in specific 
RMDs, such as RA, they are alarmingly low [40]. Identifying the dosage of exercise is 
recognized as an important matter in RMD research, with studies that adopt the ACSM 
guidelines on exercise dosage, reporting significantly higher benefits in pain of people with 
OA, compared to those not adhering to the equivalent guidelines [74]. Whether the same 
stands true for the dosage of exercise on inflammatory responses is not currently known and 
has not been investigated in RMD research 
The exercise dosage from the studies included in the two available systematic reviews 
on inflammation and exercise in RMDs [9, 10] was collectively within the dosage suggested 
by the ACSM.FITT principle details were missing from the older studies due to lack of 
exercise dosage recommendations at the time.  However, even more recent exercise studies 
are, unfortunately, characterized by the same issues. Research scientists investigating 
exercise and health outcomes in RMDs should do much better in reporting the FITT 
principles of the exercise interventions they conduct in order to understand better the effects 
of different doses of exercise. The exact same issues are present in other areas of 
investigation, whereby the FITT principles are also not adequately reported, such as exercise 
and cancer research [75]. In addition to this, the recent EULAR physical recommendations 
also do not focus on the dosage of exercise on different health outcomes in RMDs [7].  
Within these ongoing limitations, targets for exercise dosage should exist and 
appropriately tested. These targets should comply with the ACSM exercise dosage (Table 1), 
given that multiple different benefits are seen in the general population, people with non-
communicable disease [72] as well as RMDs [7, 76-78]. The same is true for inflammation. It 
is important for exercise programs to consider the baseline levels of functional ability and 
cardiorespiratory fitness of people with RMDs, as well as their preferences in order to tailor 
exercise programs, and most importantly, to apply the exercise intensity in a progressive 
manner, to avoid injury. So, although lower intensities can be applied at the early stages of an 
exercise intervention, the intensity of the exercise should progressively build up within a few 
weeks, to reach the ACSM suggested dosage, as an optimal way of improving disease-related 











 In the general population, there seems to be biological plausibility suggesting that 
exercise may promote an acute and long-term anti-inflammatory phenotype 
 The potential anti-inflammatory effects of exercise may blunt biological pathways 
that associate with and/or cause comorbidities  
 In people with rheumatic and musculoskeletal disease, the anti-inflammatory effects 
of exercise may help manage inflammation and inflammation-driven comorbidities 
better, however, research evidence is still at preliminary stages 
 The dosage of exercise requires individualization while at the same time it needs to 
adhere to specific targets (frequency, intensity, time and type) in order to optimize the 
management of symptoms in rheumatic and musculoskeletal diseases as well as other 




There is biological plausibility that the benefits of short- and long-term exercise on 
inflammation seen in the general population and populations with other non-communicable 
diseases could be extended in rheumatic and musculoskeletal diseases (RMDs), but in the 
absence of relevant basic, epidemiological and clinical trial evidence specifically in RMDs, 
firm conclusions cannot be made.  
 
To understand the effects of exercise on inflammation in rheumatic and musculoskeletal 
diseases, appropriately designed and powered studies should aim to address the following 
aspects: 
 What are the effects of exercise on markers of inflammation (CRP and/or ESR) in 
people with RMDs?  
 What are the associations between different levels, types and intensities of physical 
activity and/or exercise and inflammatory markers in RMDs?  
 How does exercise work in the context of pharmacological therapy, particularly 




In the general population and populations living with non-communicable disease there is 
evidence to suggest that exercise has anti-inflammatory effects. Relevant studies in RMDs 
are very few, possibly due to the complexity of studying relevant mechanisms in the context 
of high-grade inflammatory disorders and their treatments. More targeted research is required 
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